Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL11773422 | 0.95 | DGKA (0.52) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL28882233 | 0.94 | DGKA (0.60) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL25703869 | 0.93 | DGKA (0.63) | DGKAMAPTDNM1NAAAALDH1A1 | |
| SCHEMBL28489926 | 0.93 | DGKA (0.58) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL2392335 | 0.93 | DGKA (0.63) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL2399726 | 0.93 | DGKA (0.63) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL29360551 | 0.93 | DGKA (0.63) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL5491369 | 0.93 | DGKA (0.63) | DGKAMAPTDNM1NAAAALDH1A1 | |
| SCHEMBL20377189 | 0.92 | DGKA (0.57) | DGKAMAPTATMDNM1CYP3A4 | |
| SCHEMBL11221629 | 0.92 | DGKA (0.53) | DGKAMAPTATMDNM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113278608-B | Chloroform substitute reagent for nucleic acid extraction and separation | 杭州新景生物试剂开发有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-113278608-A | Chloroform substitute reagent for nucleic acid extraction and separation | 杭州新景生物试剂开发有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-111868627-A | Photosensitive resin composition, cured film, color conversion substrate, image display device, and method for producing cured film | 东丽株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-108250369-A | A kind of preparation method of low smell high-weatherability polymer polyatomic alcohol | 万华化学集团股份有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-9801851-B2 | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-14 | — | — | US | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | DGKA 3277/4885MAPT 4877/4885ATM 3121/4885 |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | ABL1, BCR, ABL2 | DGKA 493/4885MAPT 2776/4885ATM 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.